Acute Intermittent Porphyria (AIP) is a rare autosomal dominant metabolic disorder caused by a deficient activity of the enzyme porphobilinogen deaminase (PBGD). The disease is characterized by acute attacks of abdominal pain, vomiting, and neurological manifestations like paralysis and mental issues.
The diagnosis of AIP can be confirmed through elevated urinary levels of porphobilinogen during an acute attack. Sodium benzoate and hematin therapy are main treatment options for Acute Intermittent Porphyria Market. However, management and prevention of acute attacks still remains a challenge.
The acute intermittent porphyria market is estimated to be valued at USD 1.43 Billion in 2024 and is expected to reach USD 2.17 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031.
Get more insights on: Acute Intermittent Porphyria Market